For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Amylyx Pharmaceuticals, Inc. (AMLX) one of those stocks right now? Let's take a closer look at the stock's year-to-date performance to find out.Amylyx Pharmaceuticals, Inc. is one of 955 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Elanco Animal Health Incorporated (ELAN) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Elanco Animal Health Incorporated is one of 956 individual stocks in the Medical sector. Collectively, these companies sit at #5 in the Zacks Sector Rank. ...

If you are looking for a stock that has a solid history of beating earnings estimates and is in a good position to maintain the trend in its next quarterly report, you should consider Option Care (OPCH) . This company, which is in the Zacks Medical - Outpatient and Home Healthcare industry, shows potential for another earnings beat.This infusion and home care services company has seen a nice streak of beating earnings estimates, especially when looking at the previous two reports. The average surprise for t ...

Quest Diagnostics (DGX) came out with quarterly earnings of $2.6 per share, beating the Zacks Consensus Estimate of $2.51 per share. This compares to earnings of $2.3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +3.59%. A quarter ago, it was expected that this medical laboratory operator would post earnings of $2.57 per share when it actually produced earnings of $2.62, delivering a surprise of +1.95%.Over the last four qua ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Even ...

Company Overview - Addus HomeCare Corporation (ADUS) is currently experiencing significant activity in the options market, particularly with the Oct 17, 2025 $130 Call option showing high implied volatility, indicating potential for a major price movement [1] - The company holds a Zacks Rank 3 (Hold) in the Medical - Outpatient and Home Healthcare industry, which is positioned in the top 35% of the Zacks Industry Rank [3] Analyst Insights - Over the past 60 days, one analyst has raised the earnings estimate for the current quarter from $1.52 to $1.53 per share, while no analysts have lowered their estimates, suggesting a positive outlook [3] - The high implied volatility in options trading may signal that traders are anticipating a significant price movement for Addus HomeCare shares, which could indicate a developing trading opportunity [4] Options Trading Strategy - Options traders often seek out options with high implied volatility to sell premium, a strategy that can capture decay and potentially reduce risk if the underlying stock does not move as much as expected [4]

Core Insights - The Zacks Medical - Outpatient and Home Healthcare industry is experiencing a significant shift towards digital healthcare, driven by rising demand for telemedicine and AI-powered services, particularly due to an aging global population and increasing healthcare costs [1][4][10] Industry Overview - The industry includes companies providing outpatient care using advanced medical technologies for diagnosis, treatment, and rehabilitation, with a focus on innovation and value-based care models [3] - The global home healthcare market was valued at $416.4 billion in 2024 and is projected to reach $747.70 billion by 2030, growing at a CAGR of approximately 10.2% [1] Major Trends - Aging Population: The growing elderly population is a primary driver for home healthcare services, as older individuals prefer receiving care in familiar home settings [4] - Cost Effectiveness: Outpatient clinics offer cost-effective care, reducing the financial burden on patients and healthcare systems [5] - AI's Role: AI enhances patient care through remote monitoring and data analysis, facilitating timely interventions and improving care management [7] - Technological Advancements: Virtual assistants and chatbots are increasingly used to assist patients in managing their care and appointments [8] Staffing Challenges - The U.S. healthcare industry faces severe staffing shortages, particularly among home health aides, exacerbated by high burnout rates and international migration of health workers [11] Market Performance - The industry has underperformed compared to the S&P 500, losing 0.5% over the past year, while the S&P 500 rose by 18.2% [14] - The industry's current valuation is at a forward P/E of 19.6X, compared to the S&P 500's 23.4X [18] Company Highlights - **Quest Diagnostics**: Anticipates 2025 revenue growth of 9.9% and earnings growth of 9.1%, with a current ROE of 15.2% [21][22][25] - **DaVita**: Expected revenue growth of 5% and earnings growth of 12.9% for 2025, with an impressive ROE of 369.4% [26][27][30] - **Addus HomeCare**: Forecasts a 21.5% increase in revenues and a 16.5% rise in earnings for 2025, with a ROE of 9.4% [31][32][34] - **The Pennant Group**: Projects a 26.5% growth in revenues and a 21.3% increase in earnings for 2025, with a ROE of 9.9% [35][36][37]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell even higher, with the expectation that established trends will continue [1] Company Overview: Aveanna Healthcare (AVAH) - Aveanna Healthcare currently holds a Momentum Style Score of B, indicating potential for solid momentum [3] - The company has a Zacks Rank of 1 (Strong Buy), which historically outperforms the market when combined with a Style Score of A or B [4] Performance Metrics - Over the past week, AVAH shares increased by 2.68%, while the Zacks Medical - Outpatient and Home Healthcare industry rose by 0.41% [6] - In a longer timeframe, AVAH's monthly price change is 12.22%, significantly outperforming the industry's 0.49% [6] - Over the last quarter, AVAH shares surged by 66.25%, and gained 52.74% over the past year, compared to the S&P 500's increases of 10.66% and 18.43% respectively [7] Trading Volume - The average 20-day trading volume for AVAH is 1,164,474 shares, which serves as a bullish indicator when combined with rising stock prices [8] Earnings Outlook - In the past two months, four earnings estimates for AVAH have been revised upwards, with no downward revisions, boosting the consensus estimate from $0.22 to $0.42 [10] - For the next fiscal year, four estimates have also moved upwards without any downward revisions [10] Conclusion - Considering the positive performance metrics and earnings outlook, AVAH is positioned as a 1 (Strong Buy) stock with a Momentum Score of B, making it a compelling option for investors seeking short-term gains [12]

Company Performance - Aveanna Healthcare (AVAH) has seen a stock increase of 16.9% over the past month, reaching a new 52-week high of $8.45 [1] - Year-to-date, Aveanna's stock has gained 84.3%, significantly outperforming the Zacks Medical sector, which has seen a decline of 0.7%, and the Zacks Medical - Outpatient and Home Healthcare industry, which has returned 10.3% [1] Earnings and Revenue - Aveanna has a strong record of positive earnings surprises, having met or exceeded earnings consensus estimates in the last four quarters [2] - In the latest earnings report on August 7, 2025, Aveanna reported an EPS of $0.18, surpassing the consensus estimate of $0.04, and beat the revenue estimate by 9.93% [2] - For the current fiscal year, Aveanna is projected to post earnings of $0.41 per share on revenues of $2.31 billion, reflecting a 600% increase in EPS and a 14.24% increase in revenues [3] - For the next fiscal year, expected earnings are $0.48 per share on revenues of $2.43 billion, indicating year-over-year changes of 15.48% and 5.07%, respectively [3] Valuation Metrics - Aveanna's current valuation metrics show a Price-to-Earnings (P/E) ratio of 20.3X for the current fiscal year, slightly below the peer industry average of 20.7X [7] - On a trailing cash flow basis, Aveanna trades at 51.4X compared to the peer group's average of 18.1X, suggesting it is not in the top echelon from a value perspective [7] Zacks Rank and Style Scores - Aveanna holds a Zacks Rank of 1 (Strong Buy) due to rising earnings estimates, which aligns with the recommendation for investors to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [8] - The company has a Value Score of B, a Growth Score of A, and a Momentum Score of C, resulting in a combined VGM Score of A [6] Industry Comparison - The Medical - Outpatient and Home Healthcare industry ranks in the bottom 61% of all industries, but Aveanna and its peer, Encompass Health Corporation (EHC), show potential for growth despite the overall industry ranking [11] - EHC has a Zacks Rank of 2 (Buy) and has reported strong earnings, with expected earnings of $5.24 per share on revenues of $5.92 billion for the current fiscal year [10]

Company Performance - DaVita HealthCare (DVA) stock decreased by 3.26% to $132.26, underperforming the S&P 500 which gained 0.3% [1] - Over the past month, DVA shares increased by 3.51%, while the Medical sector rose by 7.07% and the S&P 500 by 2.09% [1] Financial Projections - DaVita is expected to report an EPS of $3.29, reflecting a growth of 27.03% year-over-year [2] - Revenue is forecasted to be $3.4 billion, indicating a 4.27% increase compared to the same quarter last year [2] Annual Estimates - For the fiscal year, earnings are projected at $10.93 per share and revenue at $13.46 billion, representing growths of 12.91% and 5.01% respectively from the previous year [3] - Recent analyst estimate revisions suggest a positive outlook for DaVita's business [3] Valuation Metrics - DaVita has a Forward P/E ratio of 12.51, which is lower than the industry average of 20.96 [6] - The company's PEG ratio stands at 0.98, compared to the industry average PEG ratio of 1.94 [6] Industry Context - The Medical - Outpatient and Home Healthcare industry is ranked 152 by Zacks, placing it in the bottom 39% of over 250 industries [7] - The Zacks Industry Rank indicates that top-rated industries outperform the lower-rated ones by a factor of 2 to 1 [7]